BioCryst
Pharmaceuticals, BCRX today announced that it has submitted a New
Drug Application (NDA) filing for intravenous (i.v.) peramivir
to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an
indication as the first i.v. neuraminidase inhibitor approved in the
U.S. for the treatment of acute uncomplicated influenza in adults.
Peramivir is approved in Japan and Korea for the treatment of influenza.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in